Analysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Target Price at $3.75

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have earned an average rating of “Hold” from the eight research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $3.75.

A number of research firms have weighed in on HOWL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. HC Wainwright dropped their price target on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Bank of America cut their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Finally, Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th.

Insider Activity at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Luke Evnin sold 108,606 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $0.61, for a total value of $66,249.66. Following the sale, the director owned 2,550,674 shares in the company, valued at $1,555,911.14. This trade represents a 4.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $171,395.36. Following the sale, the insider owned 6,007,122 shares of the company’s stock, valued at approximately $7,328,688.84. This trade represents a 2.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,628,304 shares of company stock worth $6,294,191 in the last quarter. 23.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently modified their holdings of HOWL. Charles Schwab Investment Management Inc. raised its stake in shares of Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares in the last quarter. Nuveen LLC purchased a new position in Werewolf Therapeutics during the 1st quarter worth $71,000. MPM Asset Management LLC increased its holdings in Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the period. MPM Bioimpact LLC raised its position in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Trading Up 3.6%

Shares of HOWL stock opened at $0.63 on Monday. Werewolf Therapeutics has a 1 year low of $0.56 and a 1 year high of $2.38. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. The stock’s 50 day simple moving average is $1.02 and its two-hundred day simple moving average is $1.28. The company has a market cap of $30.75 million, a PE ratio of -0.39 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Research analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.